NASDAQ · LXEO
Healthcare · Biotechnology
$5.06
Down-$0.18 (-3.56%)
Updated Aug 21, 2026, 11:21 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
LXEO does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning LXEO.
LXEO research
Company profile and research snapshot.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 25, 2026 | JP Morgan | Overweight | — |
| May 11, 2026 | Chardan Capital | Buy | — |
| Jan 13, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 13, 2026 | Chardan Capital | Buy | — |
| Dec 18, 2025 | Raymond James | Strong Buy | — |
No generated briefing is available yet.
Benzinga · Aug 12, 2026
Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 50 percent increase over losses of $(0.60) per share from
SeekingAlpha · Jun 30, 2026
Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia June 29, 2026 2:00 PM EDTCompany...
Benzinga · Jun 25, 2026
JP Morgan analyst Tessa Romero maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and lowers the price target from $12 to $9.
SeekingAlpha · Jun 22, 2026
Track Lexeo gene therapy and LX2006 for FA cardiomyopathyâpivotal SUNRISE-FA 2 path, topline data in 2H2027, risks & funding outlook. Click here to read more.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LXEO.
